Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9352W HIGH $4.96
Volume
24.79 K
Value Traded
25.04 K
Short % Float
0.1%
Days to Cover
1.0
-15.58%Week
-13.7%1 Month
-52.85%3 Month
-62.68%6 Month
-82.53%5 Year
-45.6%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.06 M
EPS (TTM)
-3.30
P/E Ratio
-
Ent. Value
10.37 M
Total Shares
6.26 M
Float Shares
5.15 M
Insiders
17.90%
Institutions
36.29%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
NAII Catalyst Timeline
Dated clinical, regulatory and corporate events for Natural Alternatives International, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Natural Alternatives International, Inc.
56Total events
1Upcoming
14Tier-1 (high impact)
2004 to 2026Coverage
Upcoming catalysts 1
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 50
▼Manufacturing MilestoneCMC / Inspection
Non-cash impairment charge on Carlsbad, CA manufacturing facility due to underutilization
▼Quarterly UpdateCorporate
NAI reports YTD FY2026 net loss of $7.2 million on net sales of $108.0 million
▲Product LaunchTriBsynPost-Market
Launch of TriBsyn beta-alanine product
Dietary supplementationsource ↗
▲Product LaunchPost-Market
Launch of CarnoSyn 4x beta-alanine product
Foods, beverages, powders, supplementssource ↗
▲Debt Royalty FinancingCorporate
NAI enters new Loan and Security Agreement with Legacy Corporate Lending, LLC
▲Partnership / LicenseCorporate
Multi-year exclusive manufacturing agreement with The Juice Plus+ Company
▲IP Litigation RulingIP / Competition
Settlement of patent infringement claims against Woodbolt
◆IP Litigation RulingIP / Competition
Filed unfair competition and false advertising complaint against Creative Compounds Inc.
▲IP Litigation RulingIP / Competition
Dismissal of all product liability suits against NAI involving CarnoSyn beta-alanine
▲IP Litigation RulingIP / Competition
Settlement of patent infringement dispute with BPI Sports and Image Sports
▲IP Litigation RulingIP / Competition
Settlement with Vital Pharmaceutical, Inc. (VPX) in patent litigation
▲Partnership / LicenseCorporate
Renewed licensing agreement with Compound Solutions, Inc. for CarnoSyn beta-alanine
◆IP Litigation RulingIP / Competition
Amended complaint filed against DNP International Co., Inc.
▲Partnership / LicenseCorporate
Supply agreement with Nestlé Nutrition for SR CarnoSyn beta-alanine
▲Partnership / LicenseCorporate
Licensing agreement with Compound Solutions, Inc. for Carnosyn beta-alanine
▲Quarterly UpdateCorporate
Fourth quarter fiscal 2008 revenue update: total revenues ~$25.2 million
●Quarterly UpdateCorporate
Revenue expected to exceed Q4 fiscal 2007 and be in line with Q1 fiscal 2007
▼Quarterly UpdateCorporate
Late filing of Annual Report on Form 10-K for fiscal year ended June 30, 2007
●Management ChangeCorporate
Retirement of Chief Scientific Officer John A. Wise effective June 30, 2007
▲Other Regulator MilestoneEx-US Regulatory
NAIE receives second Swiss pharmaceutical license from Swissmedic
▼Quarterly UpdateCorporate
Q3 FY2007 revenue guidance: in line to slightly lower than prior year Q3
▲Quarterly UpdateCorporate
First quarter fiscal 2007 revenue increase of 15% to $25.2 million
◆Timing GuidancePresentation
Call center integration for Dr. Cherry Pathway to Healing product line expected to be completed in first quarter of fiscal 2007
▲Quarterly UpdateCorporate
Fourth quarter net income of $0.16 per diluted share on revenues of $34.2 million
●Management ChangeCorporate
John Dullea assumes additional responsibilities as Executive Vice President; Tim Belanger and Mark Zimmerman leave company
▲Quarterly UpdateCorporate
Record fourth quarter net sales in excess of $33 million for three months ended June 30, 2006
●Quarterly UpdateCorporate
Announced second quarter net income of $461,000 on net sales of $19.9 million for quarter ended December 31, 2005
◆AcquisitionCorporate
Acquired Real Health Laboratories, Inc. with $5.6 million net cash used, funded partly by $3.8 million term debt obtained on December 5, 2005
●Other Regulator MilestoneEx-US Regulatory
Scheduled Therapeutic Goods Administration certification review
Past FDA Catalysts and PDUFA Decisions
How NAII actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every NAII program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| WOLF KENNETHOfficer (President, COO, & Sec.) | Disposition | -5,151 126,831 held | $2.73 | 03/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NAII
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NAII for Q2 2026. | ||||
Ownership Trends
NAII Short Interest
Shares sold short, counted twice a month.
0.1%
Short % of Float
of tradable shares sold short
5.3K
Shares Sold Short
+23.6% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
15.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NAII ranks across every disease it competes in
Competitive Position is a premium feature
See how NAII ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNAII News
NAII▲ +1.7%today
Natural Alternatives International, Inc. Announces Fiscal 2027 Q1 Results
Natural Alternatives International, Inc. reported a net loss of $2.5 million for Q1 2027, a significant drop from a $0.3 million loss in Q1 2026. Net sales fell by 25.5% to $28.1 million, driven by decreased orders in private-label manufacturing. The company is consolidating operations and exploring strategic alternatives to enhance shareholder value.
Read more →NAII▼ -13.5%on this news
Natural Alternatives International, Inc. Announces Fiscal 2026 Q4 and YTD Results
Natural Alternatives International, Inc. reported a significant net loss of $13.5 million for Q4 of fiscal 2026, largely due to a $10.4 million impairment charge on its Carlsbad manufacturing facility. Despite a 10% increase in annual net sales, the company is consolidating operations to improve efficiency. CEO Mark A. Le Doux emphasized efforts to strengthen financial stability and align operations with market demand.
Read more →NAIINatural Alternatives International, Inc. Announces 2026 Q3 and YTD Results
Natural Alternatives International, Inc. reported a net loss of $4.3 million for Q3 2026, despite a 23% increase in net sales to $35.5 million. The growth was driven by a rise in private-label contract manufacturing sales. However, the company faced operational losses due to underutilization of factory capacities and anticipates a net loss for the entire fiscal year. A new loan agreement aims to support future growth initiatives.
Read more →NAIICarnoSyn® Brands Expands TriBsyn® Applications Across Beverage, Dairy, and Medical Nutrition
Natural Alternatives International, Inc. (NAI) announced the expansion of TriBsyn®, its advanced carnosine booster, into beverage, dairy, and medical nutrition markets. This versatile ingredient supports wellness benefits such as healthy aging and cognitive function. TriBsyn® is backed by over 55 clinical studies and is designed to meet evolving consumer preferences for accessible wellness products.
Read more →NAII▼ -26.8%on this news
Natural Alternatives International, Inc. Announces 2026 Q2 and YTD Results
Natural Alternatives International, Inc. reported a net loss of $2.6 million for Q2 2026, despite a slight increase in net sales to $34.8 million. The company experienced growth in private-label contract manufacturing sales but anticipates a net loss for the full fiscal year due to reduced customer forecasts and delayed product launches. Cash reserves stood at $3.8 million as of December 31, 2025.
Read more →NAII▲ +19.6%on this news
Natural Alternatives International, Inc. Announces 2026 Q1 Results
Natural Alternatives International, Inc. reported a net loss of $0.3 million for Q1 2026, an improvement from a $2.0 million loss in Q1 2025. Net sales rose 13.8% to $37.7 million, driven by increased private-label contract manufacturing. The company anticipates returning to profitability in the second half of fiscal 2026 despite ongoing supply chain challenges.
Read more →NAIINatural Alternatives International, Inc. Announces Fiscal 2025 Q4 and YTD Results
Natural Alternatives International, Inc. reported a net loss of $7.2 million for Q4 2025, a significant increase from a loss of $1.9 million in Q4 2024. Despite a 15% rise in net sales to $33.9 million, the company faced non-recurring charges impacting its financial results. Looking ahead, NAI anticipates a net loss in the first half of fiscal 2026 but expects profitability in the latter half.
Read more →NAIINatural Alternatives International, Inc. Announces New Manufacturing Agreement with The Juice Plus+® Company
Natural Alternatives International, Inc. (NAI) announced a new multi-year manufacturing agreement with The Juice Plus+ Company. This agreement extends their 30-year partnership and covers Juice Plus+ products sold in over 24 markets worldwide. Both companies expressed confidence in the mutual benefits of this continued collaboration.
Read more →NAIINatural Alternatives International, Inc. Announces Amended and Extended Credit Facility with Wells Fargo Bank
Natural Alternatives International secured an amended credit facility with Wells Fargo Bank, extending the term to December 31, 2026, and setting borrowing capacity at $10 million. CEO Mark A. Le Doux cited the company's strong balance sheet as the basis for this agreement. The firm intends to use these funds to support working capital needs while pursuing revenue growth.
Read more →NAIINatural Alternatives International, Inc. Announces 2025 Q3 and YTD Results
Natural Alternatives International, Inc. reported a net loss of $2.2 million for Q3 2025, compared to a loss of $1.6 million in Q3 2024. Despite a 14% increase in net sales to $28.8 million, the company faced challenges with decreased beta-alanine revenue and rising operational costs. The CEO expressed optimism about future sales growth and new product launches.
Read more →NAII▲ +5.1%on this news
Natural Alternatives International and CarnoSyn® Brands Publish Clinical Research Demonstrating TriBsyn™ Delivering Exceptional Bioavailability, Increased Efficiency and Paresthesia Elimination
Natural Alternatives International and CarnoSyn® Brands published positive results for TriBsyn™, showing it significantly increases beta-alanine bioavailability while eliminating paresthesia. The study demonstrated a 4.5-fold increase in plasma beta-alanine levels compared to conventional forms. TriBsyn™ offers a new standard in beta-alanine supplementation, particularly beneficial for active aging individuals.
Read more →NAIINatural Alternatives International, Inc. Announces 2025 Q2 and YTD Results
Natural Alternatives International, Inc. reported a net loss of $2.2 million for Q2 2025, despite a 35% increase in net sales to $34.1 million. The growth was driven by a 40% rise in private-label contract manufacturing sales. However, the company anticipates a net loss for the second half of fiscal 2025 due to increased costs and a shift in sales mix.
Read more →NAIINatural Alternatives International, Inc. Announces 2025 Q1 Results
Natural Alternatives International, Inc. reported a net loss of $2.0 million for Q1 2025, compared to a $0.7 million loss in the prior year. Net sales decreased by 2.4% to $33.2 million, primarily due to reduced orders from a major customer. However, CarnoSyn® beta-alanine sales rose significantly, and the company expects to achieve net income in the latter half of the fiscal year.
Read more →NAII▲ +7.9%on this news
CarnoSyn® Brands Announces New U.S. Distribution Agreement With B&D Nutritional Ingredients
CarnoSyn® Brands has entered a distribution agreement with B&D Nutritional Ingredients, effective October 1, 2024. B&D will distribute NAI's new carnosine booster, TriBsyn™, which enhances beta-alanine absorption and targets various consumer groups. This partnership aims to increase awareness and growth of TriBsyn™, launched in August 2024.
Read more →NAII▼ -13.2%on this news· ran to -30% by day 3
Natural Alternatives International, Inc. Announces Fiscal 2024 Q4 and YTD Results
Natural Alternatives International, Inc. reported a net loss of $1.9 million for Q4 FY 2024, a decline from a net income of $2.0 million in the same quarter last year. Total net sales fell 18% to $29.5 million, driven by reduced orders from a major customer. The company anticipates a net loss in the first half of FY 2025 but expects profitability in the second half.
Read more →NAIICarnoSyn® Brands Showcasing TriBsyn™ at the 46th ESPEN Congress On Clinical Nutrition & Metabolism
Natural Alternatives International will exhibit TriBsyn™ at the ESPEN Congress in Milan from September 7-10. The patent-pending formula increases beta-alanine absorption while eliminating paresthesia. Aaron Starr called the product a game changer for dietary supplements. The company plans to attend the EuGMS Congress in Valencia next.
Read more →NAIICarnoSyn® Brands Unveils TriBsyn™ - “The World’s First Paresthesia-Free Beta-Alanine Powder”
Natural Alternatives International, Inc. (NAI) launched TriBsyn™, a new beta-alanine powder that eliminates the common paresthesia side effect. This innovation enhances beta-alanine absorption by over four times, making it suitable for older adults and those on plant-based diets. The product will debut at the 46th ESPEN Congress in Milan, Italy.
Read more →NAIINatural Alternatives International, Inc. Announces New Multi-Year Exclusive Manufacturing Agreement with The Juice Plus+ Company
Natural Alternatives International, Inc. Announces New Multi-Year Exclusive Manufacturing Agreement The Juice Plus+ Company CARLSBAD, Calif., August 11, 2017 - Natural Alternatives International, Inc. ("NAI") (NASDAQ:NAII), a leading formulator, manufacturer and marketer of cu
Read more →NAIINATURAL ALTERNATIVES INTERNATIONAL
NATURAL ALTERNATIVES INTERNATIONAL, INC. SETTLES PATENT INFRINGEMENT CLAIMS AGAINST WOODBOLT SAN MARCOS, Calif., March 21, 2016 -- Natural Alternatives International, Inc. ("NAI") (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplemen
Read more →About Natural Alternatives International, Inc.
Headquarters1535 FARADAY AVENUE, CARLSBAD, CA, 92008-7319
BIOPHARMAWATCH ELITE
Trade the next NAII catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime